This bill amends the Controlled Substances Act to define xylazine and place it on Schedule III, while carving out explicit lawful possession pathways tied to veterinary use, government animal-control, and wildlife programs. It adds xylazine to federal distribution tracking (ARCOS), orders the Sentencing Commission to review penalties for xylazine offenses, and directs two DEA/FDA reports to Congress on illicit prevalence and supply sources.
The law layers enforcement with transitional accommodations: manufacturers and practitioners get temporary relief from some Schedule III security, labeling, and registration requirements while the agencies expedite regulatory submissions. The combination aims to reduce illicit human use of xylazine without unintentionally blocking legitimate animal-care and wildlife functions—but it also raises practical and enforcement trade-offs for veterinarians, manufacturers, and law enforcement agencies.
At a Glance
What It Does
The bill adds xylazine (including salts and isomers) to Schedule III, requires DEA/FDA reporting on its illicit prevalence and origins, and requires ARCOS reporting for xylazine transactions. It narrows who counts as an ‘ultimate user’ for xylazine to people and entities receiving xylazine from veterinarians or pharmacies via veterinary prescription, and to authorized animal‑control and wildlife programs.
Who It Affects
Veterinarians, veterinary pharmacies, manufacturers of xylazine, DEA and FDA compliance staff, law enforcement agencies that investigate drug diversion, and agencies running animal-control and wildlife programs. It also affects the U.S. Sentencing Commission’s treatment of xylazine-related convictions.
Why It Matters
Putting xylazine on Schedule III brings federal control, tracking, and potential criminal penalties to a substance increasingly linked to human illicit use, while the veterinary-only possession carve‑out tries to preserve legitimate animal care. The ARCOS addition and mandated reports will provide new federal visibility into production and diversion patterns that previously were fragmented.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill begins by inserting a statutory definition of xylazine into the Controlled Substances Act that covers the parent compound, salts, isomers, and salts of isomers. That sets the legal baseline so later scheduling language clearly applies to commonly encountered forms.
Next, it places any material containing any quantity of xylazine into Schedule III, bringing it within the CSA’s regulatory framework for manufacturing, distribution, and criminal liability.
Recognizing that most lawful uses are veterinary or government animal-control/wildlife related, the bill changes the ‘‘ultimate user’’ definition specifically for xylazine. Only persons who received xylazine dispensed by a registered veterinarian or a pharmacy on a veterinarian’s prescription may possess it as an ‘‘ultimate user,’’ and the statute explicitly lists animal ownership, care, authorized government animal-control programs, and wildlife programs as permissible uses.
The definition also clarifies that government agencies, businesses that house animals, and their employees or agents are covered when acting in scope.To ease the shift to Schedule III, the bill temporarily suspends or phases in several compliance requirements: it exempts current manufacturers from immediate capital expenditures to meet Schedule III security standards, delays labeling/packaging/distribution obligations for one year, and postpones practitioner registration, inventory, and recordkeeping duties for 60 days (with an allowance for practitioners who apply during that period to continue operations pending approval). The FDA and DEA are instructed to facilitate and expedite manufacturer submissions related to the schedule change.On tracking and enforcement, the bill amends ARCOS provisions to require reporting for xylazine transactions—bringing manufacture and distribution data into the federal automated reporting system used for other controlled substances.
It directs the U.S. Sentencing Commission to review and, if appropriate, revise guidelines and commentary for offenses involving xylazine, taking account of common formulations and co‑use with other scheduled drugs. Finally, the Attorney General (through DEA) and the FDA must report to Congress on illicit prevalence, diversion points, sources, and whether analogues pose abuse risks—initially within 18 months and again with an update at four years.
The Five Things You Need to Know
The bill places any quantity of xylazine (and its salts/isomers) on Schedule III of the Controlled Substances Act, making manufacture, distribution, and possession subject to federal controls.
It redefines ‘ultimate user’ for xylazine so lawful possession is limited to material dispensed by a registered veterinarian or pharmacy on a veterinary prescription, and to animals owned, cared for, or in authorized animal‑control or wildlife programs.
Manufacturers are exempted from immediate Schedule III security capital upgrades, labeling/packaging rules are delayed for one year, and practitioner registration/inventory/recordkeeping requirements are delayed for 60 days with a pending‑application continuation rule.
The bill adds xylazine to ARCOS reporting, expanding federal tracking of production and distribution chains for the substance.
The Sentencing Commission must review applicable guidelines for xylazine offenses, and DEA/FDA must report to Congress on illicit prevalence, diversion sources, and potential analogues at 18 months and again at four years.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Statutory definition of xylazine
This section inserts a new paragraph into the CSA’s definitions to define ‘xylazine’ broadly to include salts, isomers, and salts of isomers. Practically, that prevents manufacturers or traffickers from arguing that a chemically related form falls outside the statute and ensures the scheduling language later in the bill covers typical commercial and illicit variants.
Placement of xylazine on Schedule III
The bill amends Schedule III to list any material containing xylazine. That categorization triggers the array of Schedule III controls—registration, recordkeeping, and potential criminal penalties—subject to the transitional delays and carve‑outs the bill creates. Schedule placement also determines regulatory jurisdiction for DEA and informs state enforcement alignment.
Narrowed ‘ultimate user’ definition and transition rules
This multi‑part section replaces the general ‘ultimate user’ paragraph with a specific subparagraph for xylazine, limiting lawful non‑commercial possession to items dispensed by registered veterinarians or pharmacies under veterinary prescription and to government/authorized animal programs. The provision also (a) exempts existing manufacturers from immediate capital security upgrades tied to Schedule III; (b) delays label/packaging/distribution obligations for one year; (c) delays practitioner registration/inventory/recordkeeping for 60 days while allowing applicants to continue operating during review; and (d) directs FDA and DEA to expedite manufacturer regulatory submissions. Finally, it clarifies that ultimate users as defined do not need to register under the CSA.
ARCOS reporting and data collection
This amendment inserts xylazine into the list of substances that must be reported through ARCOS and adjusts cross‑references to the Food, Drug, and Cosmetic Act as needed. Including xylazine in ARCOS brings federal transaction-level visibility—manufacturing and distribution data—into a system law enforcement and regulators already use to spot suspicious patterns for other controlled substances.
Sentencing Commission review
The bill tasks the U.S. Sentencing Commission with reviewing sentencing guidelines and commentary for offenses under federal drug distribution and import/export statutes as applied to xylazine. The Commission is explicitly asked to consider common forms and co‑use with other drugs, signaling potential guideline adjustments or clarifications to account for xylazine’s role in polysubstance chains.
DEA/FDA reporting to Congress
This section requires the Attorney General (via DEA and coordinated with FDA) to provide Congress with an initial report within 18 months on where illicit xylazine is diverted, where it originates, and whether analogues present abuse risks, and to deliver an updated report within four years. Those reports are intended to inform enforcement, regulatory, and health responses.
This bill is one of many.
Codify tracks hundreds of bills on Criminal Justice across all five countries.
Explore Criminal Justice in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Federal and state law enforcement—gains standardized ARCOS data on xylazine production and distribution, improving the ability to detect diversion patterns and prioritize investigations.
- Public health and overdose prevention programs—receives mandated federal reporting that should improve understanding of prevalence, supply chains, and analogue emergence to guide harm‑reduction responses.
- Government animal‑control and wildlife programs—receives an explicit statutory authorization to possess and use xylazine under the narrow ‘ultimate user’ carve‑out, reducing legal uncertainty for program operations.
- Pharmaceutical manufacturers—get an expedited administrative pathway and temporary relief from immediate capital and labeling requirements, giving time to adapt production and compliance systems.
Who Bears the Cost
- Veterinarians and veterinary pharmacies—face new registration, recordkeeping, and eventual labeling and security obligations under Schedule III, creating administrative burden and potential compliance costs.
- Smaller veterinary practices and animal shelters—may encounter disproportionate compliance costs and operational disruption when inventory and security requirements take effect.
- Federal agencies (DEA, FDA) and the Sentencing Commission—must allocate staff and resources to implement ARCOS changes, expedite manufacturer reviews, produce the mandated reports, and review sentencing policy.
- Suppliers engaging in cross‑border trade—could face stricter federal scrutiny and potential enforcement actions, raising legal and logistical compliance costs.
Key Issues
The Core Tension
The central dilemma is balancing tighter federal control and visibility to curb illicit human use against preserving necessary access for veterinary, animal‑control, and wildlife purposes; tightening controls reduces available legal supply (and may curb diversion) but also risks driving supply underground, increasing enforcement complexity, and imposing compliance burdens on small veterinary providers and public animal programs.
The bill tries to thread a narrow needle: it imposes federal controls and reporting while carving out lawful veterinary and government animal usages. That carve‑out reduces immediate harm to legitimate animal care but creates enforcement complexity.
Prosecutors and investigators will need to establish provenance (veterinary dispensing versus illicit possession) in cases involving human use, which may complicate investigations and evidence handling. The ARCOS data will improve visibility of legal supply chains but will not directly capture illicit imports or chemical production occurring outside regulated channels, leaving gaps in the government’s ability to trace sources.
The transition periods reduce near‑term disruption but raise timing risks. Delaying labeling for a year and practitioner recordkeeping for 60 days gives manufacturers and practitioners breathing room but also creates a temporary window in which diversion could continue with fewer controls.
The Sentencing Commission review may lead to sentencing increases or clarifying amendments; however, tougher penalties risk disproportionate impacts on low‑level actors and do not by themselves reduce supply or demand. The bill also leaves open how regulators will treat novel xylazine analogues or derivatives chemically close but not identical to the statutory definition, and how federal rules will align with state veterinary medicine laws and animal‑welfare protocols.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.